The Man, The Diagnosis, The Experiment

Richard Scolyer was not a man who gave up easily.

Diagnosed in 2023 with glioblastoma — one of the most lethal brain cancers known to medicine, with a median survival of roughly 15 months — the Sydney pathologist did what very few people could: he helped design his own experimental treatment.

Scolyer and his long-time research partner, Professor Georgina Long, had spent years developing immunotherapy breakthroughs for advanced melanoma. Skin cancer that once seemed fatal in its late stages became manageable — sometimes curable — because of their work.

When glioblastoma came for Scolyer, he and Long asked a direct question: could the same immunotherapy approach work on brain tumors?

They didn't wait for someone else to find out.

The Treatment No One Had Tried Before

Scolyer underwent an experimental treatment based on the melanoma research he and Long had developed together. The approach: prime the immune system before tumor removal, rather than after, giving the body a fighting chance to recognize and attack cancer cells.

No one had done this for glioblastoma. It was a calculated risk on an otherwise fatal diagnosis.

He survived well beyond the statistical expectation. The fact that his case generated enough promising data to launch an early-stage clinical trial in the United States reflects the results.

That trial is now running. It exists because Scolyer volunteered himself.

The Letter He Wrote

Scolyer announced his own death in an open letter — composed in advance. That tells you who this man was.

"I wanted to keep contributing, even in my darkest hour," he wrote, according to BBC News. "I pen this letter as a final goodbye to all those I have had the immense privilege of loving, sharing life's adventures with, working alongside and meeting during what can only be described as a life filled with happiness, optimism, opportunity and passion."

No self-pity. No bitterness. Pure scientist to the end.

Australian Prime Minister Anthony Albanese called him "one of our brightest lights and one of our biggest hearts," adding: "Every day, this remarkable man — the cancer specialist who became his own subject — took us into his confidence, and he lifted us all in the process."

In 2024, Scolyer and Long were jointly named Australian of the Year — a recognition of both their melanoma work and the courage of Scolyer's public battle with glioblastoma.

The Significance for Oncology

Most mainstream coverage has treated this as a moving human-interest story. It is that. But it's also a landmark moment in oncology.

Glioblastoma kills roughly 15,000 Americans every year, according to the American Brain Tumor Association. Survival rates have barely moved in decades. The standard of care — surgery, radiation, temozolomide chemotherapy — extends life by months, not years. No major breakthroughs have shifted the median survival curve meaningfully since the mid-2000s.

Scolyer's case is one data point. One. And clinical medicine doesn't move on one data point.

But the US clinical trial his case triggered is now enrolling patients. If the pre-surgical immunotherapy approach works even partially — if it buys patients six more months, or twelve, or triggers durable remission in a subset of cases — that represents a shift in a field that has stalled.

The obituaries are celebrating the man. They should also be asking why glioblastoma research has been so chronically underfunded relative to its death toll, and whether Scolyer's self-experimentation will finally disrupt the institutional inertia that has left patients with almost no options for 20 years.

For glioblastoma patients today, the honest answer is: nothing changes immediately.

The US clinical trial is early-stage. Results are years away. The pathway from "one remarkable patient survived longer than expected" to "this is now standard of care" is long, expensive, and uncertain.

But the intellectual framework Scolyer and Long built — that the immune system can be trained to fight tumors before surgery creates chaos in the tumor microenvironment — is now being tested in a rigorous setting.

Richard Scolyer spent his career saving other people's lives. At the end, he spent his remaining time making sure his own death might save more.